| abstract |
This document relates to solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof, and Instructions. Provided herein are formulations involving 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide (Compound I), Process, solid form and method of use. In another aspect, provided herein are methods for the preparation of certain compounds, including Compound I described herein, and intermediates useful in such methods. In certain aspects, the solid form of Compound I is used to inhibit a kinase, eg, JNK1 or JNK2, in a cell expressing the kinase. In another aspect, the solid form of Compound I is for use in the treatment or prevention of one or more disorders selected from the group consisting of interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection or lupus. |